Contract Manufacturing Market Opportunities for Antibody Drug Conjugates
This expert trend report is an indispensable resource for understanding the technical developments in the Antibody Drug Conjugate (ADC) sector and the scale of the commercial opportunities and risks for CMOs.
The CDMO sector is investing significant resources to expand its capabilities in the ADC arena. More than 20 companies are active in the sector although, to date, no single company…
In-Licensed Drug Products Can Signal Outsourcing Opportunity
Of the more than 230 New Molecular Entities (NMEs) approved between 2003-2013, over one-third were in-licensed by the sponsor receiving the approval. A significant difference in manufacturing status emerged between…
CDMO and CRO Outlook: Robust Market Conditions Augur Growth, More M&A Activity Ahead
Emerging bio/pharmaceutical companies are benefitting from a surge in financing from venture capital, IPOs and secondary offerings. Funding raised in the first half of 2014 is double what was raised in the same period of 2013. R&D spending by global bio/pharma companies, including funds supporting emerging company partners, continues to…